UFH may reduce 28 d mortality and improve the clinical efficacy for sepsis patients without bleeding complications. We call for large multicenter RCTs to evaluate the clinical value of UFH in sepsis patients because of the moderate quality of this body of evidence.
Ang: Angiopoietin; APACHE II: Acute Physiology and Chronic Health Evaluation II; APC: Activated protein C; APTT: Activated partial thromboplastin time; AT: Antithrombin; CIs: Confidence intervals; CMeSH: Chinese Medical Subject Headings; CRRT : Continuous Renal replacement therapy; DIC: Disseminated intravascular coagulation; F: Factor; IQR: Interquartile range; ISTH: International Society on Thrombosis & Haemostasis; KLF-5: Kruppel-like factor 5; LMWH: Low molecular weight heparin; LOS: Length of stay; MeSH: Medical Subject Headings; MD: Mean differences; MODS: Multiple organ dysfunction syndrome; NF-kB: Nuclear factor-κB; PLT: Platelet; PRISMA: Preferred Reporting Items for the Systematic Reviews and Meta-Analyses; PT: Prothrombin time; RCTs: Randomized controlled trials; RevMan: Review Manager; rhAPC: Recombinant human APC; rhTM: Recombinant human thrombomodulin; RoB2: Risk of Bias tool 2; RR: Relative risk; SIRS: Systemic inflammatory response syndrome; SSC: Surviving Sepsis Campaign; TFPI: Tissue factor pathway inhibitor; TM: Thrombomodulin; UFH: Unfractionated heparin.
We acknowledge all staff who helped perform this study.
This work was supported by the National Natural Science Foundation of China (Grant No. 81671936).
Availability of data and materials
Ethics approval and consent to participate
Consent for publication
BMC Anesthesiol. 2022;22(28) © 2022 BioMed Central, Ltd.